News >

FDA Schedules ODAC Meetings for Pexidartinib in TGCT and Quizartinib in AML

Gina Columbus @ginacolumbusonc
Published: Friday, Apr 19, 2019

The FDA has scheduled an Oncologic Drugs Advisory Committee (ODAC) hearing for May 14, 2019, to discuss a new drug application (NDA) for pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication